Diligence memo · auto-generated · as of July 2, 2026
Inflammasome Therapeutics, Inc.
Inflammasome Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Inflammasome Therapeutics, Inc. operates in Pharma, based in NEWTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Inflammasome Therapeutics, Inc. has raised $6.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.8M on 2023-08-04.
Most recent recorded round closed around 2024-12-02.
Valuation (modeled)modeled
Provath models Inflammasome Therapeutics, Inc. at approximately $9.4M (range $1.9M–$22M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.69× the median modeled value of Seed Pharma companies in 2022–2024 (18 peers) — value vs value, same stage and era. Within the normal band (69% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 19 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 58% of Pharma peers (310 compared).
Modeled value ranks above 34% of those peers.
Closest niche peers: Seal Rock Therapeutics, Inc., Diligent Pharma, Inc., A28 Therapeutics, Inc., Centaurus Therapeutics, Inc., Pathfinder Oncology, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.